ClinicalTrials.gg
Not yet recruitingNCT07121101Updated Aug 13, 2025

To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hip Arthroplasty

A Phase 2 interventional study of TRD205 tablets and TRD205 tablets in Postoperative Analgesia After Unilateral Hip Arthroplasty, sponsored by Beijing Tide Pharmaceutical Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Beijing Tide Pharmaceutical Co., Ltd (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a phase IIa, multicenter ,randomized, double-blind, placebo-controlled study designed to evaluate the safety, efficacy and kinetic characteristics of TRD205 tablets for postoperative analgesia after unilateral hip arthroplasty

Read the detailed description

This study used a placebo as a control to explore the safety, efficacy and pharmacokinetic characteristics of multiple administration of different doses of TRD205 tablets for postoperative analgesia after unilateral total hip replacement surgery

02

Conditions studied

  • Postoperative Analgesia After Unilateral Hip Arthroplasty

Keywords

  • TRD205、postoperative analgesia after unilateral hip arthroplasty
03

In context

Lead sponsor

Beijing Tide Pharmaceutical Co., Ltd is the lead sponsor of 14 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understand the purpose and significance of this study, voluntarily participate in this study, voluntarily sign the form, and voluntarily comply with the trial procedures;
  • 18 to 80 years of age, male or female;
  • 18 kg/m 2 ≤ ≤ 32 kg/m 2 , Incl. Cutoff ;
  • (ASA) physical status I to II (Appendix 6);
  • Unilateral total hip arthroplasty under general anesthesia is planned, and PCIA analgesia is expected to be required within 48 hours after surgery;
  • Able to understand the study procedures and the use of various scales involved in this study, and able to communicate effectively with the investigators.

Exclusion criteria

Exclusion Criteria:

  • Known allergies or to the drug and other drugs that may be used during the trial, and those who are not suitable for participating in the trial judged by the investigator;
  • Use the following drugs within 5 half-lives before randomization (subject to the actual drug instructions, if the half-life is unknown, wash out according to 48h), including but not limited to: analgesic drugs (except specified in the protocol), anticonvulsants, sedative-hypnotic drugs (except used according to the protocol), anxiolytics, antidepressants, enzyme inhibitors or inducers, etc., use of Chinese herbal medicine with clear analgesic effect assessed by the investigator within 7 days before randomization; sign the ICF to successfully use intra-articular injection of cocktail therapy (specific drugs include but not limited to local anesthetics such as ropivacaine, lidocaine, bupivacaine; analgesics such as morphine; drugs such as dexamethasone and methylprednisolone); refer to the list of prohibited drugs for specific types;
  • Patients who cannot take oral drugs after surgery as judged by the investigator;
  • Combining the following:

    1. Patients who received ipsilateral hip surgery within 1 year before randomization;
    2. Patients who received hip surgery within 3 months before randomization;
    3. Patients scheduled for unilateral hip revision surgery;
    4. Patients who receive total hip arthroplasty due to developmental dysplasia of the hip Type III-IV (see Appendix 9 for Crowe classification), femoral or acetabular tumor, femoral neck fracture and/or femoral neck fracture (excluding old femoral neck fracture, which is treated with internal fixation removal + total hip arthroplasty), and are not suitable for this study at the investigator's discretion;
    5. Patients planning to undergo surgery at other sites at the same time during the study;
  • Concomitant with other pain conditions that may confound the postoperative pain evaluation as judged by the investigator;
  • Sitting systolic blood pressure ≤ 90 mmHg at screening, or sitting diastolic blood pressure ≤ 50 mmHg at screening, and abnormalities as judged by the investigator;
  • Heart rate \< 50 beats/min or heart rate > 100 beats/min during the screening period, and clinically significant abnormalities as judged by the investigator; or > 450 ms in males and QTcF > 470 ms in females [calculated by Fridericia's formula: QTcF = QT/(RR0.33)]; or participants with a history of severe arrhythmia such as type II atrioventricular block or above, or a history of cardiac insufficiency;
  • Patients complicated with severe liver, kidney, cardiovascular and cerebrovascular diseases, metabolic system diseases, and should not participate in this trial at the discretion of the investigator;
  • Participants with malignant tumor who are not suitable for participating in the study as judged by the investigator;
  • Patients complicated with mental system diseases (such as schizophrenia, depression, etc.), dementia, migraine, history of epilepsy, and unsuitable for participating in the trial judged by the investigator;
  • History of psychotropic drug and narcotic drug abuse, drug abuse and alcoholism within 1 year before randomization, i.e., those who drink more than 2 units of alcohol on average per day (1 unit = 360 mL of beer or 45 mL of 40% liquor or 150 mL of wine);
  • Abnormal blood routine at screening: \< 1.5 × 10 9 /L; count \< 100 × 10 9 /L; (Hb) \< 80 g/L;
  • Abnormal liver function in the screening period: and/or AST ≥ 1.5 times the , or total ≥ 1.5 times the upper limit of normal;
  • Abnormal renal function in the screening period: serum creatinine (Cr) ≥ 1.5 times the upper limit of normal and/or dialysis participants;
  • Abnormal coagulation function during screening period: (PT) prolonged by more than 3 seconds and/or activated partial thromboplastin time (APTT) prolonged by more than 10 seconds;
  • Patients with positive syphilis antibody (Syphilis TP) and antibody (HIV-Ab) tests during the screening period who are not suitable for participating in the trial at the investigator's discretion;
  • Pregnant or lactating women;
  • Those who are unwilling or unable to take effective measures during the study or 30 times after the study;
  • Participated in other drug or device clinical study within 3 months before randomization (signed ICF and received the investigational drug/device or placebo treatment, for medication or treatment, start timing);
  • Other conditions that the investigator considers inappropriate for participation in the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    200mg treatment group

    Administered orally every 12 hours for a total of four times;Take 400mg tablets for the first time and 200mg each for the other three times.

    Drug: TRD205 tablets

  • Experimental
    400mg treatment group

    Administered orally every 12 hours for a total of four times;Take800mg tablets for the first time and 400mg each for the other three times.

    Drug: TRD205 tablets

  • Experimental
    600mg treatment group

    Administered orally every 12 hours for a total of four times;Take 1200mg tablets for the first time and 600mg each for the other three times.

    Drug: TRD205 tablets

  • Placebo comparator
    Placebo

    Administered orally every 12 hours for a total of four times;Take 6 tablets for the first time and 3 tablets each for the other three times

    Drug: placebo

Interventions

  • Administered orally every 12 hours for a total of four times;Take TRD205 2 tablets and Placebo 4 tablets for the first time ,TRD205 1 tablets and Placebo 2 tablets each for the other three times

  • Administered orally every 12 hours for a total of four times;Take TRD205 4 tablets and Placebo 2 tablets for the first time ,TRD205 2 tablets and Placebo 1 tablets each for the other three times.

  • Administered orally every 12 hours for a total of four times;Take TRD205 6 tablets and Placebo 0 tablets for the first time ,TRD205 3 tablets and Placebo 0 tablets each for the other three times.

  • Drugplacebo

    Administered orally every 12 hours for a total of four times;Take Placebo 6 tablets for the first time ,Placebo 3 tablets each for the other three times.

06

What researchers measure

Primary outcomes

  1. Treatment-Related Adverse Events

    By evaluating security metrics such as AEs, SAEs and TEAEs to evaluate the safety of multiple administration of TRD205 tablets in patients with postoperative analgesia after unilateral hip arthroplasty.

    Time frame: 5 days

  2. The total dose of morphine was administered to the patient 0 to 48 hours after the operation

    To evaluate the efficacy of multiple administration of TRD205 tablets in patients with postoperative analgesia after unilateral hip arthroplasty

    Time frame: Within 48 hours after the first administration

Secondary outcomes

  1. Peak Plasma Concentration(Cmax)

    To evaluate the pharmacokinetic (PK) of multiple administration of TRD205 tablets in patients with postoperative analgesia after unilateral hip arthroplasty

    Time frame: From 1 hour before the first administration to 48 hours after the last administration.

  2. Minimum concentration (Cmin)

    To evaluate the pharmacokinetic (PK) of multiple administration of TRD205 tablets in patients with postoperative analgesia after unilateral hip arthroplasty

    Time frame: From 1 hour before the first administration to 48 hours after the last administration

  3. Time to peak(Tmax)

    To evaluate the pharmacokinetic (PK) of multiple administration of TRD205 tablets in patients with postoperative analgesia after unilateral hip arthroplasty

    Time frame: From 1 hour before the first administration to 48 hours after the last administration

  4. elimination half life(T1/2)

    To evaluate the pharmacokinetic (PK) of multiple administration of TRD205 tablets in patients with postoperative analgesia after unilateral hip arthroplasty

    Time frame: From 1 hour before the first administration to 48 hours after the last administration

  5. Area under the plasma concentration versus time curve (AUC)

    To evaluate the pharmacokinetic (PK) of multiple administration of TRD205 tablets in patients with postoperative analgesia after unilateral hip arthroplasty

    Time frame: From 1 hour before the first administration to 48 hours after the last administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Nov 2025, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 13, 2025
StartEst.
Sep 26, 2025
Primary completionEst.
Nov 20, 2025
CompletionEst.
Dec 27, 2025
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07121101
Collaborators
The Third Affiliated Hospital of Southern Medical University
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Sep 26, 2025 (estimated)
Primary completion
Nov 20, 2025 (estimated)
Completion
Dec 27, 2025 (estimated)
Last update
Aug 13, 2025

Study contacts

yingying wang
Contact
wangyy6@tidepharm.com
+ 86-10-6788-0648-5064

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRD205

Start the discussion